We have located links that may give you full text access.
A real-world comparison among third-generation antiseizure medications: results from the COMPARE study.
Epilepsia 2023 December 6
OBJECTIVE: There is little comparative data on the third-generation antiseizure medications (ASMs). We aimed to assess and compare the effectiveness of brivaracetam (BRV), eslicarbazepine acetate (ESL), lacosamide (LCM) and perampanel (PER) in people with epilepsy (PWE). Efficacy and tolerability were compared as secondary objectives.
METHODS: A multicenter, retrospective study collecting data from 22 Italian neurology/epilepsy centres. All adult PWE who started add-on treatment with one of the studied ASMs between January 2018 and October 2021 were included. Retention rate was established as effectiveness measure and described using Kaplan-Meier curves and the best fitting survival model. The responder status and the occurrence of adverse events (AEs) were used to evaluate efficacy and safety, respectively. The odds of AEs and drug-efficacy were estimated by two multilevel logistic models.
RESULTS: 960 patients (52.92% females, median age 43 years) met the inclusion criteria. They mainly suffered from structural epilepsy (52.29%) with monthly (46.2%) focal seizures (69.58%). Compared with LCM, all the studied ASMs had a higher drop-out risk, statistically significant in the BRV levetiracetam (LEV)-naïve (HR: 1.97; 95% CI: 1.17-3.29) and PER groups (HR: 1.64; 95% CI: 1.06-2.55). Women were at higher risk of discontinuing ESL (HR: 5.33; 95% CI: 1.71-16.61), as well as PER-treated patients with unknown epilepsy aetiology vs those with structural aetiology (HR: 1.74; 95% CI: 1.05-2.88). BRV with prior LEV therapy showed lower odds of efficacy (OR: 0.08; 95% CI: 0.01-0.48) vs LCM, whilst a higher efficacy was observed in women treated with BRV and LEV-naïve (OR: 10.32; 95% CI: 1.55-68.78) vs men. PER (OR: 6.93; 95% CI: 3.32-14.44) and BRV in LEV-naïve patients (OR: 6.80; 95% CI: 2.64-17.52) had a higher chance of AEs than LCM.
SIGNIFICANCE: Comparative evidence from real-world studies may help clinicians to tailor treatments according to patients' demographic and clinical characteristics.
METHODS: A multicenter, retrospective study collecting data from 22 Italian neurology/epilepsy centres. All adult PWE who started add-on treatment with one of the studied ASMs between January 2018 and October 2021 were included. Retention rate was established as effectiveness measure and described using Kaplan-Meier curves and the best fitting survival model. The responder status and the occurrence of adverse events (AEs) were used to evaluate efficacy and safety, respectively. The odds of AEs and drug-efficacy were estimated by two multilevel logistic models.
RESULTS: 960 patients (52.92% females, median age 43 years) met the inclusion criteria. They mainly suffered from structural epilepsy (52.29%) with monthly (46.2%) focal seizures (69.58%). Compared with LCM, all the studied ASMs had a higher drop-out risk, statistically significant in the BRV levetiracetam (LEV)-naïve (HR: 1.97; 95% CI: 1.17-3.29) and PER groups (HR: 1.64; 95% CI: 1.06-2.55). Women were at higher risk of discontinuing ESL (HR: 5.33; 95% CI: 1.71-16.61), as well as PER-treated patients with unknown epilepsy aetiology vs those with structural aetiology (HR: 1.74; 95% CI: 1.05-2.88). BRV with prior LEV therapy showed lower odds of efficacy (OR: 0.08; 95% CI: 0.01-0.48) vs LCM, whilst a higher efficacy was observed in women treated with BRV and LEV-naïve (OR: 10.32; 95% CI: 1.55-68.78) vs men. PER (OR: 6.93; 95% CI: 3.32-14.44) and BRV in LEV-naïve patients (OR: 6.80; 95% CI: 2.64-17.52) had a higher chance of AEs than LCM.
SIGNIFICANCE: Comparative evidence from real-world studies may help clinicians to tailor treatments according to patients' demographic and clinical characteristics.
Full text links
Related Resources
Trending Papers
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app